| Value | ₹11.65 Cr |
|---|---|
| Execution period | Within approximately one month |
BSE filing, NSE: DODLA. Summary written from the filing by ALFA Finder's alert engine.
Dodla Dairy Ltd: key numbers
- Share price
- ₹985.95
- Market cap
- ₹5,948 Cr
- Revenue (annual)
- ₹4,125 Cr
- Net profit (annual)
- ₹267.0 Cr
- P/E (TTM)
- 27.6×Sector 40.6×
- Promoter holding
- 58.92%+0.00% QoQ
- FII holding
- 6.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dodla Dairy Ltd
All →Dodla Dairy Earnings Call Transcript: Key Takeaways
Dodla Dairy delivered solid revenue growth but faced intense raw milk inflation. Margin compression is evident despite price hikes as input costs rose faster.
Dodla Dairy Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹1,196 Cr (+17.4% YoY), EBITDA ₹64.1 Cr (5.4% margin, -30.9%), PAT ₹36.6 Cr (-44.3%). Milk procurement costs compressed gross margin to 23.1%.
Dodla Dairy Results Update
Dodla Dairy's press release shows Q2 FY27 revenue up 17.4% but PAT down 44.3%. It also flags a proposed 40% stake in a joint venture with MIHL.
Dodla Dairy Q2 FY27 Results: Net Profit ₹36.6 Cr, Down 44.3% YoY
Dodla Dairy Ltd reported revenue from operations of ₹1,196 Cr (+17.4% YoY) and net profit of ₹36.6 Cr (-44.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹36.6 Cr · -44.3% YoY
Dodla Dairy Legal & Regulatory
Dodla Dairy clarified media reports on FSSAI proceedings, stating no formal prosecution order exists and emphasizing its commitment to food safety standards.
Dodla Dairy Board Meeting Date
Dodla Dairy has scheduled a board meeting for 28 October 2026 to consider Q3 unaudited standalone and consolidated financial results. No other agenda items are disclosed.
Other merger & restructuring announcements
All →Narayana Hrudayalaya Merger & Restructuring
Narayana Hrudayalaya's NCLT Bengaluru bench sanctioned the demerger of clinical services from its subsidiary NH Integrated Care. Order uploaded today; effectiveness awaits certified copy filings.
Abans Enterprises Merger & Restructuring
Abans Enterprises' board approved voluntary liquidation of wholly owned subsidiary AGJT, subject to shareholder approval. Completion is expected within one year.
- Execution
- Expected within one year, subject to approvals and statutory formalities
Max Estates Merger & Restructuring Worth ₹0.01 Cr
Max Estates will subscribe to 10,000 shares worth ₹1 lakh in a yet-to-be-incorporated real estate company. The entity awaits Ministry of Corporate Affairs approval.
- Value
- ₹0.01 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹29 Cr
Aurobindo Pharma approved transferring 100% of Auro Pharma LLC, Russia, between wholly owned subsidiaries. Cash consideration is about INR 29 crore, subject to adjustments.
- Value
- ₹29.00 Cr
- Execution
- 60-90 days
Choice International Merger & Restructuring Worth ₹1.27 Cr
Choice International sold a unit or subsidiary to Arrowbridge Trade for Rs.1.275 Crore in cash. The buyer is unrelated and the deal is at arm's length.
- Value
- ₹1.27 Cr
Shringar House of Mangalsutra Merger & Restructuring Worth ₹5 Cr
Shringar House of Mangalsutra will incorporate a wholly owned jewellery subsidiary, subscribing Rs 5 Crore in cash. The subsidiary becomes a related party once formed.
- Value
- ₹5.00 Cr